May 21 |
Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
|
May 20 |
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
|
May 16 |
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
|
May 16 |
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
|
May 10 |
Biotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout
|
May 9 |
The 3 Best Biotech Stocks to Buy in May 2024
|
May 8 |
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
|
May 8 |
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
|
May 8 |
Q1 2024 Halozyme Therapeutics Inc Earnings Call
|
May 8 |
Halozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ...
|